Results 171 to 180 of about 154,358 (318)

Incidence of Cardiac Arrhythmias During Anesthesia [PDF]

open access: bronze, 1960
William A. Sims   +2 more
openalex   +1 more source

Inter‐atrial block as a predictor of adverse outcomes in patients with HFpEF

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Inter‐atrial block (IAB), a marker of electrical atrial dysfunction, is associated with an increased risk of atrial fibrillation (AF) and adverse events in various populations. The prognostic impact of IAB in heart failure (HF) with preserved ejection fraction (HFpEF) remains unknown.
Jerremy Weerts   +11 more
wiley   +1 more source

The Impact of Quality of Life on Cardiac Arrhythmias: A Clinical, Demographic, and AI-Assisted Statistical Investigation. [PDF]

open access: yesDiagnostics (Basel)
Nechita LC   +6 more
europepmc   +1 more source

The state-of-the-art technic of stereotactic radioablation for the treatment of cardiac arrhythmias: An overview. [PDF]

open access: yesHealth Sci Rep, 2023
MasoudKabir F   +12 more
europepmc   +1 more source

Incidence of atrial fibrillation in patients with an insertable cardiac monitor and symptomatic heart failure

open access: yesESC Heart Failure, EarlyView.
Atrial fibrillation (AF) was observed in almost half of patients with insertable cardiac monitor and symptomatic heart failure (HF). One‐fourth of the patients had new onset AF and a higher rate of HF events compared with patients without AF. AF incidence was similar in HF patients with preserved versus reduced left ventricular ejection fraction ...
Muhammad Shahzeb Khan   +8 more
wiley   +1 more source

Contemporary Trends in Pulsed Field Ablation for Cardiac Arrhythmias. [PDF]

open access: yesJ Cardiovasc Dev Dis
Yavin H   +4 more
europepmc   +1 more source

Real‐world comparative effectiveness of sacubitril/valsartan versus RAS inhibition alone in patients with de novo heart failure

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Large‐scale, real‐world data on early initiation of sacubitril/valsartan in patients newly diagnosed (de novo) with HF with reduced ejection fraction (HFrEF) are limited. We examined the effectiveness of sacubitril/valsartan versus angiotensin‐converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB) on all‐cause and cause ...
Ankeet S. Bhatt   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy